Limits...
Topo2α protein expression predicts response to anthracycline combination neo-adjuvant chemotherapy in locally advanced primary breast cancer.

Mukherjee A, Shehata M, Moseley P, Rakha E, Ellis I, Chan S - Br. J. Cancer (2010)

Bottom Line: On univariate analysis, pre-chemotherapy high expression of Topo2α protein (P=0.031), and negativity for ER and EGFR (P=0.001 and P=0.005, respectively) correlated with pCR.Positivity for p53 also showed significance (P=0.015), whereas basal phenotype, HER2, and all the clinicopathological variables of LAPC included in this study did not show significant correlation with response.On multivariate analysis, Topo2α expression had the strongest correlation with pCR (P=0.021) followed by EGFR (P=0.044). the study suggests that pre-chemotherapy Topo2α protein expression measured by IHC strongly correlates with pathological CR to neo-adjuvant anthracyclines in this group of LAPC studied.

View Article: PubMed Central - PubMed

Affiliation: Department of Oncology, Nottingham University Hospitals, City Hospital Campus, Hucknall Road, Nottingham, NG5 1PB, UK.

Show MeSH

Related in: MedlinePlus

Overall survival (A) and relapse-free survival (B) analysis for patients either positive or negative for basal phenotype (BP).
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3008601&req=5

fig3: Overall survival (A) and relapse-free survival (B) analysis for patients either positive or negative for basal phenotype (BP).

Mentions: Of the relapses and deaths, 19 (61%) and 10 (47%) were Topo2α-high, respectively. However, Topo2α status did not predict either relapse-free (P=0.67) or OS (P=0.76) (Figure 2A and B). Similarly, although patients with BP tumours tend to have a worse OS and RFS, this was not statistically significant (P=0.5 and P=0.54, respectively) (Figure 3A and B).


Topo2α protein expression predicts response to anthracycline combination neo-adjuvant chemotherapy in locally advanced primary breast cancer.

Mukherjee A, Shehata M, Moseley P, Rakha E, Ellis I, Chan S - Br. J. Cancer (2010)

Overall survival (A) and relapse-free survival (B) analysis for patients either positive or negative for basal phenotype (BP).
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3008601&req=5

fig3: Overall survival (A) and relapse-free survival (B) analysis for patients either positive or negative for basal phenotype (BP).
Mentions: Of the relapses and deaths, 19 (61%) and 10 (47%) were Topo2α-high, respectively. However, Topo2α status did not predict either relapse-free (P=0.67) or OS (P=0.76) (Figure 2A and B). Similarly, although patients with BP tumours tend to have a worse OS and RFS, this was not statistically significant (P=0.5 and P=0.54, respectively) (Figure 3A and B).

Bottom Line: On univariate analysis, pre-chemotherapy high expression of Topo2α protein (P=0.031), and negativity for ER and EGFR (P=0.001 and P=0.005, respectively) correlated with pCR.Positivity for p53 also showed significance (P=0.015), whereas basal phenotype, HER2, and all the clinicopathological variables of LAPC included in this study did not show significant correlation with response.On multivariate analysis, Topo2α expression had the strongest correlation with pCR (P=0.021) followed by EGFR (P=0.044). the study suggests that pre-chemotherapy Topo2α protein expression measured by IHC strongly correlates with pathological CR to neo-adjuvant anthracyclines in this group of LAPC studied.

View Article: PubMed Central - PubMed

Affiliation: Department of Oncology, Nottingham University Hospitals, City Hospital Campus, Hucknall Road, Nottingham, NG5 1PB, UK.

Show MeSH
Related in: MedlinePlus